Amgen Inc. Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
Amgen Inc. (AMGN) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $4.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-13
- Amgen Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2018-09-30 was $50.00M.
- Amgen Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2017-06-30 was $65.00M.
- Amgen Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2013-12-31 was -$176.00M.
- Amgen Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2013-09-30 was $0.00.
- Amgen Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $4.00M, a 0.00% change from fiscal 2024.
- Amgen Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $4.00M, a 33.33% decline from fiscal 2023.
- Amgen Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $6.00M.
- Amgen Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 3 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 6 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 9 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.00M 10-K · filed 2026-02-13 | |||
| 2024-12-31 | $4.00M 10-K · filed 2026-02-13 | |||
| 2023-12-31 | $6.00M 10-K · filed 2026-02-13 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-14 | |||
| 2021-12-31 | $8.00M 10-K · filed 2024-02-14 | |||
| 2020-12-31 | $68.00M 10-K · filed 2023-02-09 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-16 | |||
| 2018-12-31 | $61.00M 10-K · filed 2021-02-09 | |||
| 2018-09-30 | $50.00M 10-Q · filed 2018-10-31 | |||
| 2017-12-31 | $28.00M 10-K · filed 2020-02-12 | |||
| 2017-06-30 | $65.00M 10-Q · filed 2017-07-26 | |||
| 2016-12-31 | $7.00M 10-K · filed 2019-02-13 | |||
| 2015-12-31 | $48.00M 10-K · filed 2018-02-13 | |||
| 2014-12-31 | $2.00M 10-K · filed 2017-02-14 | |||
| 2013-12-31 | -$176.00M derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | -$176.00M derived: sum of 2 quarters · filed 2016-10-31 | -$166.00M derived: sum of 3 quarters · filed 2016-10-31 | $24.00M 8-K · filed 2016-10-31 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $10.00M derived: sum of 2 quarters · filed 2013-10-29 | $200.00M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $10.00M 10-Q · filed 2013-08-06 | $200.00M 10-Q · filed 2013-08-06 | ||
| 2013-03-31 | $190.00M 10-Q · filed 2013-05-03 | |||
| 2012-12-31 | $30.00M 10-K · filed 2015-02-19 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $20.00M derived: sum of 2 quarters · filed 2014-02-24 | $20.00M derived: sum of 3 quarters · filed 2014-02-24 | $221.00M 10-K · filed 2014-02-24 |
| 2011-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $20.00M derived: sum of 2 quarters · filed 2011-11-04 | $221.00M 10-Q · filed 2011-11-04 | $261.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | $201.00M 10-Q · filed 2011-08-08 | $241.00M derived: sum of 3 quarters · filed 2013-02-27 | $241.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $201.00M 10-Q · filed 2011-05-10 | $241.00M derived: sum of 2 quarters · filed 2013-02-27 | $241.00M derived: sum of 3 quarters · filed 2013-02-27 | $616.00M derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $40.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $40.00M derived: sum of 2 quarters · filed 2013-02-27 | $415.00M derived: sum of 3 quarters · filed 2013-02-27 | $415.00M 10-K · filed 2013-02-27 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $375.00M derived: sum of 2 quarters · filed 2010-11-08 | $375.00M 10-Q · filed 2010-11-08 | |
| 2010-06-30 | $375.00M 10-Q · filed 2010-08-09 | $375.00M 10-Q · filed 2010-08-09 | ||
| 2009-12-31 | $60.00M 10-K · filed 2012-02-29 | |||
| 2008-12-31 | $191.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |